Drugs / ABBV-1354
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07219017 | Oct → Dec 2025 | — | AbbVie | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-1354 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07219017 ↗ |
| Known as | Icalcaprant | “Mass Balance Study of [14C] ABBV-1354 (Icalcaprant) in Healthy Male Subjects Following Single Oral Dose Administration” NCT07219017 ↗ |
| Route | Oral | “Following Single Oral Dose Administration” NCT07219017 ↗ |